{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:40:40Z","timestamp":1790538040753,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.parkreldis.2015.02.009","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T14:47:04Z","timestamp":1424357224000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Julia","family":"Muellner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Gharrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Odile","family":"Habert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-6977","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Kas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cormier-Dequaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Tahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vidailhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schuepbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2015.02.009_bib1","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/0140-6736(91)92989-F","article-title":"Parkinson's disease: pathophysiology","volume":"337","author":"Agid","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuroscience.2011.02.027","article-title":"Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"180","author":"Goldberg","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuint.2006.03.013","article-title":"Dopamine turnover is upregulated in the caudate\/putamen of asymptomatic MPTP-treated rhesus monkeys","volume":"49","author":"Pifl","year":"2006","journal-title":"Neurochem Int"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib5","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1093\/brain\/awr233","article-title":"Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease","volume":"134","author":"Nandhagopal","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0301-0082(98)00006-9","article-title":"Compensatory mechanisms in experimental and human\u00a0parkinsonism: towards a dynamic approach","volume":"55","author":"Bezard","year":"1998","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0166-2236(90)90112-N","article-title":"Compensations after lesions of central dopaminergic neurons: some clinical and basic implications","volume":"13","author":"Zigmond","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archneur.1984.04050190062015","article-title":"Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism","volume":"41","author":"Zigmond","year":"1984","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","article-title":"In\u00a0vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease","volume":"47","author":"Lee","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1399-0004.1981.tb00732.x","article-title":"The inheritance of human erythrocyte catechol-O-methyltransferase activity","volume":"19","author":"Floderus","year":"1981","journal-title":"Clin Genet"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib11","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/bi00013a008","article-title":"Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme","volume":"34","author":"Lotta","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/jnnp-2012-304475","article-title":"The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism","volume":"84","author":"Klebe","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib14","doi-asserted-by":"crossref","first-page":"082508","DOI":"10.1118\/1.4816304","article-title":"Investigating the use of nonattenuation corrected PET images for the attenuation correction of PET data","volume":"40","author":"Chang","year":"2013","journal-title":"Med Phys"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2967\/jnumed.106.038646","article-title":"Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images","volume":"48","author":"Kas","year":"2007","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/jnnp.2006.103788","article-title":"Gender differences in Parkinson's disease","volume":"78","author":"Haaxma","year":"2007","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/WNF.0b013e318205dff7","article-title":"Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients","volume":"34","author":"Maltete","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ana.22155","article-title":"The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial","volume":"69","author":"Corvol","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11307-009-0257-5","article-title":"COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in\u00a0vivo","volume":"12","author":"Hirvonen","year":"2010","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib20","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/mp.2009.36","article-title":"Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis","volume":"15","author":"Mier","year":"2010","journal-title":"Mol Psychiatry"},{"issue":"18","key":"10.1016\/j.parkreldis.2015.02.009_bib21","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1523\/JNEUROSCI.0774-07.2007","article-title":"Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease","volume":"27","author":"Williams-Gray","year":"2007","journal-title":"J\u00a0Neurosci"},{"issue":"17","key":"10.1016\/j.parkreldis.2015.02.009_bib22","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.95.17.9991","article-title":"Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior","volume":"95","author":"Gogos","year":"1998","journal-title":"Proc Natl Acad Sci U. S. A"},{"issue":"3","key":"10.1016\/j.parkreldis.2015.02.009_bib23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1124\/jpet.102.043042","article-title":"Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice","volume":"303","author":"Huotari","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.parkreldis.2015.02.009_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00213-010-1944-2","article-title":"Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice","volume":"211","author":"Tammim\u00e4ki","year":"2010","journal-title":"Psychopharmacol Berl"},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2015.02.009_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0006-8993(02)02238-2","article-title":"Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease","volume":"930","author":"Nakazato","year":"2002","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.02.009_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-003-1627-3","article-title":"D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice","volume":"172","author":"Huotari","year":"2004","journal-title":"Psychopharmacol Berl"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.02.009_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0028-3886.108121","article-title":"The COMT Val158Met polymorphism as an associated risk factor for Parkinson's disease in Asian rather than Caucasian populations","volume":"61","author":"Lechun","year":"2013","journal-title":"Neurol India"},{"issue":"7","key":"10.1016\/j.parkreldis.2015.02.009_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/FPC.0000000000000056","article-title":"COMT gene and risk for Parkinson's disease: a systematic review and meta-analysis","volume":"24","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mds.23805","article-title":"Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease","volume":"27","author":"de Lau","year":"2012","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.parkreldis.2015.02.009_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/425589","article-title":"Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain","volume":"75","author":"Chen","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib31","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.52.6.1206","article-title":"SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD","volume":"52","author":"Ichise","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2015.02.009_bib32","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1212\/WNL.0b013e3182918c2d","article-title":"Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease","volume":"80","author":"Storch","year":"2013","journal-title":"Neurology"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:14:17Z","timestamp":1761178457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802015000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1353802015000644"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.02.009","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}